There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Seres Therapeutics (NASDAQ: MCRB) and KemPharm (NASDAQ: KMPH) with bullish sentiments.
Seres Therapeutics (NASDAQ: MCRB)
In a report released today, John Newman from Canaccord Genuity maintained a Buy rating on Seres Therapeutics (NASDAQ: MCRB), with a price target of $20. The company’s shares opened today at $8.13, close to its 52-week low of $6.65.
According to TipRanks.com, Newman is a 5-star analyst with an average return of 18.4% and a 47.5% success rate. Newman covers the Healthcare sector, focusing on stocks such as Hutchison China MediTech Ltd, Synergy Pharmaceuticals Inc, and Aileron Therapeutics Inc.
Currently, the analyst consensus on Seres Therapeutics is Strong Buy and the average price target is $18, representing a 121.4% upside.
In a report issued on May 9, Oppenheimer also reiterated a Buy rating on the stock with a $18 price target.
See today’s analyst top recommended stocks >>
KemPharm (NASDAQ: KMPH)
Canaccord Genuity analyst Dewey Steadman assigned a Buy rating to KemPharm (NASDAQ: KMPH) today and set a price target of $11. The company’s shares opened today at $6.30.
According to TipRanks.com, Steadman has 0 stars on 0-5 star ranking scale with an average return of -5.3% and a 34.1% success rate. Steadman covers the Healthcare sector, focusing on stocks such as ANI Pharmaceuticals Inc, Pacira Pharmaceuticals, and Correvio Pharma Corp.
Currently, the analyst consensus on KemPharm is Strong Buy and the average price target is $12.50, representing a 98.4% upside.
In a report released yesterday, Janney Montgomery also initiated coverage with a Buy rating on the stock with a $17 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
